These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21701231)

  • 1. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
    Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
    Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
    Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Okuyama H; Ueno H; Morizane C; Kondo S; Sakamoto Y; Okusaka T; Ochiai A
    Pancreas; 2016 Jan; 45(1):110-6. PubMed ID: 26566216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
    Otake A; Tsuji D; Taku K; Kawasaki Y; Yokoi M; Nakamori H; Osada M; Matsumoto M; Inoue K; Hirai K; Itoh K
    Eur J Clin Pharmacol; 2017 Aug; 73(8):1033-1039. PubMed ID: 28487999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
    Xue P; Zhu L; Wan Z; Huang W; Li N; Chen D; Hu J; Yang H; Wang L
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1653-60. PubMed ID: 25792009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
    An SG; Kim DU; Song GA; Jang AL
    Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.
    Nakachi K; Furuse J; Ishii H; Suzuki E; Yoshino M
    Jpn J Clin Oncol; 2007 Feb; 37(2):114-20. PubMed ID: 17272317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
    Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
    Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.
    Suzuki E; Furuse J; Ikeda M; Okusaka T; Nakachi K; Mitsunaga S; Ueno H; Morizane C; Kondo S; Shimizu S; Kojima Y; Hagihara A
    Oncology; 2010; 79(1-2):39-45. PubMed ID: 21063134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
    Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
    Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
    Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
    Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Huang PW; Chang CF; Hung CY; Hsueh SW; Chang PH; Yeh KY; Chen JS; Chen YY; Lu CH; Hung YS; Chou WC
    Cancer Med; 2019 Sep; 8(12):5554-5563. PubMed ID: 31385456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
    Nakai Y; Kawabe T; Isayama H; Sasaki T; Yagioka H; Yashima Y; Kogure H; Arizumi T; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Tsujino T; Tada M; Omata M
    Oncology; 2008; 75(1-2):120-6. PubMed ID: 18784438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
    Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
    BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
    Nakai Y; Isayama H; Sasaki T; Sasahira N; Kogure H; Hirano K; Tsujino T; Ijichi H; Tateishi K; Tada M; Omata M; Koike K
    Jpn J Clin Oncol; 2010 Aug; 40(8):774-80. PubMed ID: 20462979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.